Technical Analysis for MTEM - Molecular Templates, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 2.61% | |
| Wide Bands | Range Expansion | 2.61% | |
| Up 3 Days in a Row | Strength | 2.61% | |
| Oversold Stochastic | Weakness | 2.61% | |
| Stochastic Buy Signal | Bullish | 7.27% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 8 hours ago |
| Rose Above 10 DMA | about 8 hours ago |
| Up 3% | about 8 hours ago |
| Up 2% | about 8 hours ago |
| Up 1% | about 8 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/08/2024
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Cancer Treatment Treatment Of Cancer Oncology Chemical Elements Lymphoma Oxygen Toxins Prodrugs Evofosfamide Prodrug Nitrogen Mustards
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Cancer Treatment Treatment Of Cancer Oncology Chemical Elements Lymphoma Oxygen Toxins Prodrugs Evofosfamide Prodrug Nitrogen Mustards
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.45 |
| 52 Week Low | 1.01 |
| Average Volume | 51,283 |
| 200-Day Moving Average | 3.54 |
| 50-Day Moving Average | 1.38 |
| 20-Day Moving Average | 1.21 |
| 10-Day Moving Average | 1.14 |
| Average True Range | 0.13 |
| RSI (14) | 45.65 |
| ADX | 21.66 |
| +DI | 19.43 |
| -DI | 22.92 |
| Chandelier Exit (Long, 3 ATRs) | 1.09 |
| Chandelier Exit (Short, 3 ATRs) | 1.40 |
| Upper Bollinger Bands | 1.45 |
| Lower Bollinger Band | 0.97 |
| Percent B (%b) | 0.43 |
| BandWidth | 39.40 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.09 |
| MACD Histogram | 0.0073 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.29 | ||||
| Resistance 3 (R3) | 1.29 | 1.25 | 1.27 | ||
| Resistance 2 (R2) | 1.25 | 1.23 | 1.25 | 1.26 | |
| Resistance 1 (R1) | 1.22 | 1.21 | 1.24 | 1.22 | 1.26 |
| Pivot Point | 1.18 | 1.18 | 1.19 | 1.18 | 1.18 |
| Support 1 (S1) | 1.15 | 1.16 | 1.17 | 1.15 | 1.10 |
| Support 2 (S2) | 1.11 | 1.14 | 1.11 | 1.10 | |
| Support 3 (S3) | 1.08 | 1.11 | 1.09 | ||
| Support 4 (S4) | 1.08 |
